Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes?

The pathogenesis of thrombocytopenia associated with TAD and the occurrence of overlapping traits between TAD and AITP are still a matter of debate. For this reason, we investigated for the presence and specificity of platelet and thyroid autoantibodies in 18 TAD patients with thrombocytopenia, 19 TAD patients without thrombocytopenia and in 22 patients with primary AITP without clinical signs of TAD. Platelet-associated IgG and/or specific circulating platelet autoantibodies were detected in 83% of patients with TAD and thrombocytopenia, in 10% of patients with TAD without thrombocytopenia and in 86% of patients with primary AITP. The reactivity of serum autoantibodies, assayed by MoAb immobilization of platelet antigens (MAIPA), was directed against platelet glycoproteins Ib and/or IIb/IIIa in 50% of the patients with TAD and thrombocytopenia, as in 46% of the patients with primary AITP. Thyroid autoantibodies were found in 89% of patients with TAD and thrombocytopenia, in 95% of patients with TAD without thrombocytopenia, and in 18% of patients with primary AITP. Thyrotropin (TSH) levels determined in three of four AITP patients with thyroid autoantibodies revealed a subclinical hyperthyroidism in one patient. The present study supports the autoimmune aetiology of thrombocytopenia associated with TAD, since the prevalence and specificity of platelet autoantibodies are similar in TAD and primary AITP. The results indicate also that there exists an overlap between thyroid and platelet autoimmunity with or without clinical manifestations.     

合成消旋丹参素及其衍生物对血小板聚集性和cAMP含量的影响

合成消旋丹参素(简称合成丹参素)及其衍生物(BLA、BLE)在体外实验和体内静脉注射时,对ADP诱导的家兔和大鼠血小板聚集性均有明显的抑制作用。BLK和BLE有较强的促进血小板解聚作用,而合成丹参素较弱。合成丹参索、BLA和BLE在体外实验时,无升高血小板内cAMP作用,反使其cAMP含量下降。提示合成丹参素及其衍生物对血小板功能的作用,不是通过提高cAMP水平;推测可能和抑制血栓素A_2(TXA_2)合成酶有关。     

The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1α, and its interaction with indomethacin

Summary Pre-incubation of human platelets with nifedipine in vitro or treatment of normal volunteers with nifedipine, 30 mg daily for one week, did not alter ADP induced aggregation measured by whole blood aggregometry. 6-oxo-Prostaglandin F₁ remained undetectable in plasma following oral administration of nifedipine to normal volunteers. The hypotensive response to intravenous nifedipine administration was similar in spontaneously hypertensive rats pretreated with indomethacin or placebo. These results conflict with previous reports that nifedipine alters platelet aggregation and prostaglandin metabolism.     

Effects of fenflumizole on aggregation ex vivo of human platelets and formation of thromboxane B2 and 6-keto-prostaglandin-F_{1\alpha }

Summary Fenflumizole (2-(2,4-difluorophenyl)-4,5-bis(4-methoxyphenyl)imidazole), a new non-steroidal anti-inflammatory drug, was given to healthy subjects in single oral doses of 0.1, 1 and 2 mg/kg. The effect of the drug was followed for up to 8 h by repeated tests of arachidonic acid-induced platelet aggregation and was related to its concomitant plasma concentration. Fenflumizole reversibly inhibited platelet aggregation and the degree of inhibition was found to be linearly correlated with the log plasma concentration. There was depression of the formation of thromboxane B₂ and 6-keto-prostaglandin F₁ (the stable metabolites of thromboxane A₂ and prostacyclin) in clotted whole blood measured by radioimmunoassay after fenflumizole 1 mg/kg. This effect was directly related to the concentration of the drug in plasma, the maximum effect being reached at fenflumizole concentrations >200 ng/ml. EC₅₀-values for inhibition of the formation of thromboxane B₂ and 6-keto-prostaglandin were approximately 20 and 40 ng/ml, respectively. The results suggest that orally administered fenflumizole is a potent inhibitor of platelet aggregation and prostanoid formation.     

High dose gammaglobulin therapy in adults with idiopathic thrombocytopenic purpura (ITP) clinical effects

Summary This study of the effect of high-dose intravenous gammaglobulins with one or two courses of therapy in 18 adults with idiopathic thrombocytopenia purpura showed a platelet rise in thirteen patients. The highest response rates were seen in splenectomized adults. In chronic patients the response was transient only. If therapy was effective, increased values of platelet-associated IgG were reduced, while shortened platelet survival times were prolonged. There was no influence of high-dose gammaglobulins on platelet function. Different 7S-preparations such as -propiolactone modified Ig, pH 4 treated Ig and reduced and alkylated Ig have comparable effects.Supported by the Deutsche Forschungsgemeinschaft (Mu 277/9-4)     

心痛安颗粒剂对不稳定性心绞痛患者血小板功能及凝血系统的影响

目的 :观察心痛安颗粒剂对不稳定性心绞痛患者血小板和凝血系统的作用。方法 :6 0例不稳定性心绞痛患者随机分为心痛安组 (30例 ,常规西药加心痛安颗粒剂治疗 )与对照组 (30例 ,单用常规西药治疗 ) ,观察治疗前后血小板最大聚集率 (Ma% )血小板 α颗粒膜糖蛋白 (GMP- 140 )和 D-二聚体 (D- D)的变化。结果 :治疗后 ,心痛安颗粒组的 Ma% ,GMP- 140和 D- D经治疗后明显下降 ,下降幅度明显大于对照组。结论 :心痛安颗粒剂可能通过抑制血小板聚集、活化和纤维蛋白合成而发挥治疗不稳定性心绞痛的作用。     

脑梗死急性期血小板超微结构与功能的研究

目的 :探讨脑梗死急性期血小板超微结构改变与功能变化的关系及意义。方法 :对大灶脑梗死组 2 2例 ,小灶脑梗死组 2 5例 ,对照组 2 0例进行研究 ,分别于发病后 3d内及 2周采静脉血 ,采用透射电镜观察血小板超微结构 ,酶联免疫吸附竞争法测定血小板GMP - 140、酶联免疫吸附双抗体夹心法测定血浆GMP - 140的浓度。结果 :发病后 3d内血小板超微结构改变明显 ,伪足增多 ,聚集融合成片 ,α颗粒明显减少 ,大灶组改变尤为明显。大灶组血小板GMP - 140、血浆GMP - 140浓度、血小板粘附率 (PAdT)、血小板聚集率 (PAgT)较对照组非常显著升高(P <0 0 0 1) ,小灶组上述指标也较对照组显著升高 (P <0 0 5) ,但较大灶组低。 2周后 ,血小板超微结构大灶组无明显变化 ,小灶组则明显恢复 ,2组血小板GMP - 140、血浆GPM - 140浓度均明显下降 ,但仍较对照组高 ,PAdT、PAgT均降至正常。结论 :脑梗死急性期血小板功能增强伴明显结构改变 ;血小板超微结构的改变可以作为判断病情轻重的一个可靠指标 ;血浆GMP -140浓度比PAdT和PAgT更能准确地反应血小板的活化程度     

15种理气中药体外对人血小板聚集的影响

目的观察15种理气中药对体外肾上腺素诱导的人血小板聚集的影响.方法试管内人血小板加中药孵育前后,比浊法测定血小板聚集.结果11种理气药具有抗血小板聚集作用(P＜0.05～0.001),其中枳实的抑制作用较阳性对照阿司匹林明显(P＜0.01),青皮、陈皮与阿司匹林无差异(P＜0.05).柿蒂、甘松、檀香、沉香对血小板聚集无明显作用(P＞0.05).结论多数理气药(11/15)在体外具有抗人血小板聚集作用,枳实、青皮、陈皮3种作用强于或与阿司匹林相当.     

整合素血小板膜糖蛋白IIb、IIIa在系膜增殖性肾炎中的表达

目的 :观察整合素血小板膜糖蛋白Ⅱb、Ⅲa(GPⅡb、GPⅢa)在人类系膜增殖肾炎 (MsPGN)中肾内表达 ,探讨GPⅡb Ⅲa在MsPGN的作用。方法 :18例肾活检标本均行光镜HE、PAS、PASM Masson染色 ,电镜及免疫荧光检查 ,以SABC法测定肾组织中GPⅡb、GPⅢa、P 选择素 (P 140 )、纤维连接蛋白 (FN)、粘连蛋白 (LN)表达与正常对照组分别比较 ,并行计算机图像分析。结果 :PAS阳性物 (PAS+ )、PASM阳性物 (PASM+ )及FN、LN明显增生 ;GPⅡb、GPⅢa、P 140表达上调 ;肾小球细胞数 (n)、平均肾小球体积 (AVG)及肾小球硬化指数显著增加 ;肾小管、间质轻度受损。结论 :GPⅡb、GPⅢa在肾小球及肾小管间质表达上调与系膜细胞基质增生、细胞浸润、肾小球硬化相关 ;可能与肾小球疾病中凝血功能紊乱、血小板在肾脏的致病作用相关     

降纤酶治疗急性脑梗塞后血液流变学指标的变化

目的　评定降纤酶治疗急性脑梗塞对血液凝血、纤溶系统及血小板的影响。方法　24例急性脑梗塞患者随机分为降纤酶组和常规治疗组,测定治疗前后血浆纤维蛋白原(Fg)、D-二聚体、凝血酶原时间(PT)、白陶土部分凝血活酶时间(KPTT)、血小板最大聚集率(P